• Users Online: 280
  • Print this page
  • Email this page
Year : 2018  |  Volume : 1  |  Issue : 2  |  Page : 80-83

Innovativeness in breast cancer: The prime example of anti-HER2 agents

1 Medical Oncology Department, University Hospital Waterford, Waterford, Ireland
2 Medical Oncology Department, Sligo University Hospital, Sligo, Ireland

Correspondence Address:
Yasar Ahmed
Medical Oncology Department, University Hospital Waterford, Dunmore Road, Waterford, X91 ER8E
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCO.JCO_15_18

Rights and Permissions

Since the identification of HER2 in breast cancer pathogenesis and the introduction of the first drugs targeting this receptor, the humanized monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib, many advances have been made in the treatment of HER2-positive breast cancer that have led to a progressive improvement in the outcome of patients with early and advanced breast cancer. One of the major achievements is the development of dual HER2 blockade strategies. Evidence from the neoadjuvant and metastatic setting suggests that by combining trastuzumab with other anti-HER2 drugs such as lapatinib or the humanized monoclonal antibody pertuzumab, the efficacy of treatment may be further improved.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded366    
    Comments [Add]    

Recommend this journal